CureDuchenne, as an early investor in Avidity Biosciences, is excited to share the announcement of the Phase 1/2 EXPLORE44™ clinical trial of AOC 1044 in healthy volunteers and participants with […]
At the core of the MAA submission are positive data from the pivotal Phase 2b VISION-DMD study which comprised a (1) 24-week period to demonstrate efficacy and safety of vamorolone […]
Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001 Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; programs […]
NHL All-Star Ryan Getzlaf Joins Forces with Global Nonprofit to Help Find a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (September 20, 2022) – CureDuchenne, a leading global nonprofit […]
Dr. Paolo Bettica will review recently completed study analysis for the Italfarmaco Phase 3 randomized controlled trial of givinostat in boys with Duchenne muscular dystrophy (DMD). He will answer your […]
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 4-month interim results […]
An interview with the Millers and Ryan Getzlaf discussing the Getzlaf Golf Shootout that originally aired on NBC4
